Among the millionaires who’ve made their fortunes by investing in biotech, these 20 top the list. [AlienForce - Fotolia.com]
#10. William C. Weldon
Chairman, Johnson & Johnson
Total value of common shares owned: $31,721,932
486,682 common shares owned as of Feb. 28, 2012
Closing price: $65.18
#9. James M. Cornelius
Non-executive Chairman; CEO, 2008–10, Bristol-Myers Squibb
Total value of common shares owned: $32,259,615.85
994,133 common shares owned as of Feb. 28, 2012
Closing price: $32.45
#8. Robert J. Hugin
Chairman and CEO, Celgene
Total value of common shares owned: $34,559,378.88
438,126 common shares owned as of April 18, 2012
Closing price: $78.88
#7. Kevin W. Sharer
Chairman and CEO, Amgen
Total value of common shares owned: $60,865,836.48
901,449 common shares owned as of March 26, 2012
Closing price: $67.52
#6. Joseph Jimenez
CEO, Novartis
Total value of common shares owned: $61,103,909.76
1,056,033 common shares owned as of Jan. 19, 2012
Closing price: $57.87 [Converted Sept. 27, 2012, from CHF 54.20 closing share price]
#5. Miles D. White
Chairman and CEO, Abbott Laboratories
Total value of common shares owned: $64,833,849.15
1,197,301 common shares owned as of Jan. 31, 2012
Closing price: $54.15
#4. John C. Martin, Ph.D.
Chairman and CEO, Gilead Sciences
Total value of common shares owned: $88,767,251.10
1,949,215 common shares owned as of Feb. 29, 2012
Closing price: $45.54
#3. Leonard Bell, M.D.
CEO, Alexion Pharmaceuticals
Total value of common shares owned: $93,541,944.15
1,050,915 common shares owned as of March 16, 2012
Closing price: $89.01
#2. Leonard S. Schleifer, M.D., Ph.D.
President and CEO, Regeneron Pharmaceuticals
Total value of common shares owned: $257,315,504.13
2,119,393 common shares owned as of April 11, 2012
Closing price: $121.41
#1. Phillip Frost, M.D.
Chairman, Teva Pharmaceutical Industries
Total value of common shares owned: $548,379,553
13,587,204 common shares owned as of Dec. 31, 20112
Closing price: $40.36
For U.S. CEOs, this data is typically found in their companies’ definitive 2012 proxy statements (Form DEF 14-A), though it takes a careful reading of footnotes to subtract from the listed numbers stock purchasable upon the exercise of options, or stock held in trust for benefit of family members. For CEOs of companies based outside the U.S., such data can usually, but not always, be found in their 2011 annual reports or Form 20-F filings with the SEC.
Notes:
1 On April 26, 2012, AstraZeneca announced David Brennan decided to retire from the position, amid news reports he was pushed out.
2 Does not include the 1 million shares purchased May 30, 2012 at prices ranging from $37.82 to $39.57.